Alnylam Pharmaceuticals/$ALNY
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.
- Ticker
- $ALNY
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 2,500
- Headquarters
- Cambridge, United States
- Website
- www.alnylam.com
ALNY Metrics
BasicAdvanced
$30bn
39.36
$5.62
0.27
-
Price and volume
Market cap
$30bn
Beta
0.27
52-week high
$495.55
52-week low
$197.81
Average daily volume
2.1m
Financial strength
Current ratio
3.055
Quick ratio
2.791
Long term debt to equity
198.135
Total debt to equity
220.623
Interest coverage (TTM)
3.52%
Profitability
EBITDA (TTM)
1,054.538
Gross margin (TTM)
79.65%
Net profit margin (TTM)
16.13%
Operating margin (TTM)
20.81%
Effective tax rate (TTM)
-1.10%
Revenue per employee (TTM)
$1,920,000
Management effectiveness
Return on assets (TTM)
12.34%
Return on equity (TTM)
96.55%
Valuation
Price to earnings (TTM)
39.364
Price to revenue (TTM)
6.103
Price to book
21.85
Price to tangible book (TTM)
21.85
Price to free cash flow (TTM)
35.762
Free cash flow yield (TTM)
2.80%
Free cash flow per share (TTM)
6.185
Growth
Revenue change (TTM)
95.14%
Earnings per share change (TTM)
-353.96%
3-year revenue growth (CAGR)
57.17%
10-year revenue growth (CAGR)
66.17%
3-year earnings per share growth (CAGR)
-13.27%
10-year earnings per share growth (CAGR)
2.86%
What the Analysts think about ALNY
Analyst ratings (Buy, Hold, Sell) for Alnylam Pharmaceuticals stock.
ALNY Financial Performance
Revenues and expenses
ALNY Earnings Performance
Company profitability
ALNY News
AllArticlesVideos
ALNY Investors Have Opportunity to Join Alnylam Pharmaceuticals, Inc. Fraud Investigation with SBS Law
Business Wire1 week ago
Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
Business Wire2 weeks ago
Alnylam Pharmaceuticals, Inc. (ALNY) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
Business Wire2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.